Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript February 6, 2026 Roivant Sciences Ltd. beats earnings ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ...

Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript February 6, 2026 Immunovant, Inc. beats earnings expectations. Reported EPS is $-0.60951, expectations were $-0.72. Operator: Good day, ...

Median overall survival differed significantly by race: 36.8 months for Black patients versus 48.4 months for White patients ...

Headwinds are mounting for a historically expensive stock market during Trump's second, non-consecutive term.

Canada is losing jobs, but don’t worry—it needs less of them. That was the general takeaway from Statistics Canada (StatCan) ...

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...

Gov. Kim Reynolds announced Thursday she was introducing legislation that would increase taxes on cigarettes and tobacco ...

Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming six-month pilot data for its Revita ...

Immunic presents additional phase 2 CALLIPER trial data for vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026: New York Friday, February 6, 2026, 16:0 ...

Low serum 25-hydroxyvitamin D is associated with an increased risk for respiratory tract infection hospitalization.